243 related articles for article (PubMed ID: 35279807)
1. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
Namisaki T; Kaji K; Shimozato N; Kaya D; Ozutsumi T; Tsuji Y; Fujinaga Y; Kitagawa K; Furukawa M; Sato S; Sawada Y; Nishimura N; Takaya H; Okura Y; Seki K; Kawaratani H; Moriya K; Noguchi R; Asada K; Akahane T; Mitoro A; Yoshiji H
Indian J Gastroenterol; 2022 Apr; 41(2):169-180. PubMed ID: 35279807
[TBL] [Abstract][Full Text] [Related]
2. Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.
Shimozato N; Namisaki T; Kaji K; Kitade M; Okura Y; Sato S; Moriya K; Seki K; Kawaratani H; Takaya H; Sawada Y; Saikawa S; Nakanishi K; Furukawa M; Fujinaga Y; Kubo T; Asada K; Kitagawa K; Tsuji Y; Kaya D; Ozutsumi T; Akahane T; Mitoro A; Yoshiji H
Hepatol Res; 2019 Oct; 49(10):1147-1161. PubMed ID: 31177586
[TBL] [Abstract][Full Text] [Related]
3. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis.
Namisaki T; Moriya K; Kitade M; Takeda K; Kaji K; Okura Y; Shimozato N; Sato S; Nishimura N; Seki K; Kawaratani H; Takaya H; Sawada Y; Akahane T; Saikawa S; Nakanishi K; Kubo T; Furukawa M; Noguchi R; Asada K; Kitagawa K; Ozutsumi T; Tsuji Y; Kaya D; Fujinaga Y; Yoshiji H
Hepatol Commun; 2017 Nov; 1(9):928-945. PubMed ID: 29404501
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
Namisaki T; Noguchi R; Moriya K; Kitade M; Aihara Y; Douhara A; Nishimura N; Takeda K; Okura Y; Kawaratani H; Takaya H; Seki K; Yoshiji H
J Gastroenterol; 2016 Feb; 51(2):162-72. PubMed ID: 26190501
[TBL] [Abstract][Full Text] [Related]
5. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
Fujinaga Y; Kawaratani H; Kaya D; Tsuji Y; Ozutsumi T; Furukawa M; Kitagawa K; Sato S; Nishimura N; Sawada Y; Takaya H; Kaji K; Shimozato N; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759852
[TBL] [Abstract][Full Text] [Related]
6. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Shirai Y; Yoshiji H; Noguchi R; Kaji K; Aihara Y; Douhara A; Moriya K; Namisaki T; Kawaratani H; Fukui H
J Gastroenterol Hepatol; 2013 Apr; 28(4):723-30. PubMed ID: 23301938
[TBL] [Abstract][Full Text] [Related]
7. Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.
Sawada Y; Kawaratani H; Kubo T; Fujinaga Y; Furukawa M; Saikawa S; Sato S; Seki K; Takaya H; Okura Y; Kaji K; Shimozato N; Mashitani T; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yamao J; Yoshiji H
Hepatol Res; 2019 Mar; 49(3):284-295. PubMed ID: 30365236
[TBL] [Abstract][Full Text] [Related]
8. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Shirai Y; Aihara Y; Namisaki T; Yoshii J; Yanase K; Tsujimoto T; Kawaratani H; Fukui H
Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1094-104. PubMed ID: 21372165
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.
Okura Y; Namisaki T; Moriya K; Kitade M; Takeda K; Kaji K; Noguchi R; Nishimura N; Seki K; Kawaratani H; Takaya H; Sato S; Sawada Y; Shimozato N; Furukawa M; Nakanishi K; Saikawa S; Kubo T; Asada K; Yoshiji H
Hepatol Res; 2017 Nov; 47(12):1317-1328. PubMed ID: 28029729
[TBL] [Abstract][Full Text] [Related]
11. Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats.
Wei YH; Jun L; Qiang CJ
Dig Dis Sci; 2004 Oct; 49(10):1589-94. PubMed ID: 15573910
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model.
Kim MY; Baik SK; Park DH; Jang YO; Suk KT; Yea CJ; Lee IY; Kim JW; Kim HS; Kwon SO; Cho MY; Ko SB; Chang SJ; Um SH; Han KH
J Gastroenterol; 2008; 43(11):889-96. PubMed ID: 19012043
[TBL] [Abstract][Full Text] [Related]
13. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis.
Ibañez P; Solis N; Pizarro M; Aguayo G; Duarte I; Miquel JF; Accatino L; Arrese M
J Gastroenterol Hepatol; 2007 Jun; 22(6):846-51. PubMed ID: 17565640
[TBL] [Abstract][Full Text] [Related]
14. Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-β1/Smad signaling pathway.
Ni XX; Li XY; Wang Q; Hua J
J Physiol Biochem; 2021 Feb; 77(1):35-45. PubMed ID: 33188625
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II facilitates fibrogenic effect of TGF-β1 through enhancing the down-regulation of BAMBI caused by LPS: a new pro-fibrotic mechanism of angiotensin II.
Li YS; Ni SY; Meng Y; Shi XL; Zhao XW; Luo HH; Li X
PLoS One; 2013; 8(10):e76289. PubMed ID: 24155898
[TBL] [Abstract][Full Text] [Related]
16. Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.
Nakanishi K; Kaji K; Kitade M; Kubo T; Furukawa M; Saikawa S; Shimozato N; Sato S; Seki K; Kawaratani H; Moriya K; Namisaki T; Yoshiji H
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31163617
[TBL] [Abstract][Full Text] [Related]
17. [Perindopril and losartan attenuate bleomycin A5-induced pulmonary fibrosis in rats].
Meng Y; Meng Y; Li X; Cai SX; Tong WC; Cheng YX
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):919-24. PubMed ID: 18583228
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
Kim HJ; Ryu JH; Han SW; Park IK; Paik SS; Park MH; Paik DJ; Chung HS; Kim SW; Lee JU
Nephron Physiol; 2004; 97(4):p58-65. PubMed ID: 15331931
[TBL] [Abstract][Full Text] [Related]
19. [Effect of ACE-I and AT-1 receptor blocker on the progression of CCl(4)-inducing rat hepatic fibrogenesis].
Li X; Meng Y; Zhang ZS; Yang XS; Wu PS
Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(14):1241-5. PubMed ID: 12930639
[TBL] [Abstract][Full Text] [Related]
20. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats.
Moreno M; Gonzalo T; Kok RJ; Sancho-Bru P; van Beuge M; Swart J; Prakash J; Temming K; Fondevila C; Beljaars L; Lacombe M; van der Hoeven P; Arroyo V; Poelstra K; Brenner DA; Ginès P; Bataller R
Hepatology; 2010 Mar; 51(3):942-52. PubMed ID: 20044807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
